Decoding neural signals to restore lives

Before founding INBRAIN, Aguilar spent 13 years at Medtronic, including a decade leading the company’s global neuromodulation business. … Her background in neuroscience research, including early work studying the relationship between pesticides and Parkinson’s disease, shaped a long-term interest in circuit modulation and neurotherapeutics.

The rapidly expanding brain-computer interface (BCI) field is not only driving cutting-edge neuroscience but also fueling a competitive race for market dominance. … Carolina Aguilar, CEO and founder of INBRAIN Neuroelectronics, told The Debrief in an email that her company prefers “to think in terms of implantable and non-implantable BCIs rather than simply ‘invasive’ and ‘non-invasive.’”

Després hi ha molts cofundadors de Neuralink que van sortir de l’empresa i van crear altres companyies molt competitives, com Precision Neuroscience o Science Corporation, però n’hi ha més. … INBRAIN es troba en una fase de creixement tant en infraestructures com en equip. Cap a on dirigiu la vostra evolució? L’any passat vam aconseguir una fita increïble en implantar per primera vegada una interfície de grafè al cervell humà.

Barcelona-based InBrain develops a graphene-neural BCI platform as an adjunctive therapy for treating Parkinson’s disease. In 2023, InBrain received FDA breakthrough device designation for the technology. It kicked off the first-in-human study last fall. … InBrain’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the data foundation and computational infrastructure that will help accelerate their mission to improve neurological health worldwide.”

The collaboration aims to leverage Microsoft’s large language models and data analytics tools to enable adaptation of Inbrain’s interfaces in real time. … Inbrain Neurosciences recently partnered with Mayo Clinic to accelerate the clinical development and commercialization of its BCI therapeutics for neurological disorders, and the company is also engaged in ongoing clinical research led by the University of Manchester and the Manchester Centre for Clinical

“INBRAIN’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the computational infrastructure and data foundation that will accelerate their mission to improve neurological health worldwide.” … This allows the INBRAIN system to read and influence brain signals with incredible accuracy.

Scientific and technological advances, including in neuroscience, are helping to unlock therapeutic solutions for illnesses originating from the brain and nervous system. … At INBRAIN Neuroelectronics, we believe that next-generation brain-computer interfaces must combine advanced neural materials with intelligent, adaptive systems.

At INBRAIN’s five-year anniversary event, Medtech Insight moderated a panel discussion with leading experts in neuroscience to talk about the future of BCI and neurotherapeutics.

INBRAIN Neuroelectronics is sharing encouraging interim results from the world’s first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. … The study primarily aims to assess the safety of brain-computer interface (BCI) during brain tumor surgery. … “This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology.”

BCI Inbrain Neuroelectronics has announced completion of patient recruitment in a first-in-human study evaluating its graphene-based brain-computer interface (BCI) technology. … “The ability to detect high-frequency neural activity with micrometre-scale precision and also modulate it provides a fundamentally new level of insight into brain-tumour interactions, and functional brain decoding and mapping,” said David Coope (Manchester Centre for Clinical Inbrain Neurosciences, Manchester

Barcelona-based InBrain Neuroelectronics shared interim findings from a first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. … InBrain’s implant is only 10 micrometers thick—thinner than a human hair—and is designed to safely decode and modulate neural signals with high accuracy.

The study—sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences in Manchester, UK—is evaluating the safety and functional performance of graphene-based electrodes when used during the surgical resection of brain tumours. … Regarding the potential clinical advantages of its BCI solution, Inbrain claims that graphene technology offers several benefits for neurosurgical procedures. … “This convergence of advanced materials science, neuroscience and AI [artificial intelligence] is shaping the future of real-time, precision neurology.”

In 2004, Andre Geim and Konstantin Novoselov at the University of Manchester in England achieved a breakthrough when they isolated graphene for the first time. A flat form of carbon made up of a single layer of atoms, graphene is the thinnest known material—and one of the strongest. Hailed as a wonder material, it won Geim and Novoselov a Nobel Prize in 2010. Twenty years later, graphene is finally making its way into batteries, sensors, semiconductors, air conditioners, and even headphones.

Company joins rivals like Elon Musk’s Neuralink in effort to treat neurological disorders with technology.

Just how soon might we see such things as Parkinson’s and other diseases tackled? And how? Thank you. Thank you for having me here. And hello, New York.

InBrain Neuroelectronics today shared findings from a first-in-human study of its brain-computer interface (BCI) technology. The company’s technology integrates intelligent computing and graphene-based materials to decode and modulate real-time brain activity. … The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for the resection of brain tumors … InBrain said the study has a primary objective of assessing the safety of InBrain’s BCI during brain tumor surgery. Secondary objectives include neural signal quality, brain stimulation delivery ability, performance consistency and overall sutability.

At INBRAIN Neuroelectronics, we believe that decoding the brain’s electrical language will be as transformative for neuroscience as sequencing was for genomics.

We are thrilled to share that the GphT-BCI project, led by INBRAIN Neuroelectronics in collaboration with Institut Català de Nanociència i Nanotecnologia (ICN2), is set to revolutionize brain-computer interface (BCIs) through groundbreaking graphene technology.

Inbrain’s neural implants will be used to treat conditions like Parkinson’s and epilepsy.

Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene

Inbrain develops tiny neuro-electronics — miniature interfaces that connect the nervous system with electronic devices — as next-generation neural disease solutions, which represents huge market potential with advanced material science